Consensus Builds For EU Reg Reforms As The Full Details Emerge
This article was originally published in The Gray Sheet
Executive Summary
The proposed texts for European-wide medical device and IVD regulations have won the support of the EU Commission and key Council and Parliament Committees, and, for the first time, have been posted for public review. Here is a first look at what awaits device companies with regards to EU scrutiny of high-risk devices and what negotiators settled on for oversight of single-use device reprocessing.
You may also be interested in...
Agreement Announced On EU Reg Reforms, But Consensus Is Not Complete
The Council of the European Union heralded an agreement on new EU-wide regulations for devices and diagnostics following years of preparation and negotiation. But it appears that one of the three main segments of the government structure, the European Commission, still has misgivings about single-use device reprocessing language, and one other issue, in the negotiated texts, which could make them vulnerable.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.